TABLE 6.

Clinical response at end of treatment in patients with rIFIs

Clinical response	No. (%) of patients
	Group 1 (200 mg q.i.d./400 mg b.i.d.)		Group 2 (400 mg q.i.d./600 mg b.i.d.)		Group 3 (800 mg b.i.d./800 mg q.d.)		Total
	Efficacy evaluable (n = 9)	All randomized (n = 12)	Efficacy evaluable (n = 6)	All randomized (n = 10)	Efficacy evaluable (n = 6)	All randomized (n = 10)	Efficacy evaluable (n = 21)	All randomized (n = 32)
Responder (complete + partial)	5 (56)	6 (50)	1 (17)	1 (10)	3 (50)	4 (40)	9 (43)	11 (34)
Complete	0	0	0	0	2 (33)	3 (30)	2 (10)	3 (9)
Partial	5 (56)	6 (50)	1 (17)	1 (10)	1 (17)	1 (10)	7 (33)	8 (25)
Failure	4 (44)	6 (50)	5 (83)	9 (90)	3 (50)	6 (60)	12 (57)	21 (66)
Stable disease	1 (11)	1 (8)	1 (17)	1 (10)	1 (17)	1 (10)	3 (14)	3 (9)
Clinical failure	3 (33)	3 (25)	2 (33)	2 (20)	1 (17)	1 (10)	6 (29)	6 (19)
Unable to determine	0	0	1 (17)	1 (10)	1 (17)	1 (10)	2 (10)	2 (6)
Missing	0	2 (17)	1 (17)	5 (50)	0	3 (30)	1 (5)	10 (31)